Semaglutide reduces heart attack risk by 20%

Irish Examiner May 14, 2024, 12:00 PM UTC

Summary: A study presented at the European Congress of Obesity revealed that participants taking semaglutide had a 20% lower risk of heart attack, stroke, or death due to cardiovascular disease. The research involved 17,604 adults across 41 countries, showing promising cardiovascular benefits regardless of weight loss. Semaglutide could be a groundbreaking medical breakthrough akin to statins, potentially transforming chronic diseases. Participants on semaglutide lost more weight than those on a placebo.

Full article

Article metrics
Significance5.8
Scale8.0
Magnitude7.5
Novelty7.0
Actionability6.0
Immediacy7.0
Positivity8.0
Probability0.0
Credibility8.0

Timeline:

  1. [4.7]
    New therapy targets brain's appetite center for weight loss (News-Medical.Net)
    13d
    Source
  2. [2.9]
    New weight loss shot CT-388 shows promising results (Daily Mail)
    13d
    Source
  3. [4.4]
    Dual-action drug MK-801 doubles weight loss in mice (Inside Precision Medicine)
    13d
    Source
  4. [5.5]
    Roche's CT-388 weight loss drug shows promising trial results (CNBC)
    13d

  5. [5.6]
    Wegovy sustains weight loss for at least 4 years (WIRED)
    13d

  6. [2.1]
    Novo Nordisk to study Ozempic's effects on alcohol consumption (CNN)
    14d
    Source
  7. [5.5]
    Semaglutides improve heart health by 20% beyond weight loss (The Guardian)
    14d

  8. [4.5]
    Personalized semaglutide dosing aids sustainable weight loss (News-Medical.Net)
    15d
    Source
  9. [3.2]
    Ozempic reduces heart attack risk, may help fight other diseases (Daily Mail)
    15d
    Source
  10. [5.2]
    Semaglutide (Ozempic) shows potential for treating addiction and dementia (The Guardian)
    15d

  11. [3.0]
    New weight loss jab retatrutide shows promising results (Daily Mail)
    15d
    Source
  12. [3.1]
    "Book 'Magic Pill' delves into weight loss drug Ozempic." (Mint)
    15d
    Source
  13. [5.8]
    Semaglutide reduces heart attack risk by 20% (The Guardian)
    15d

  14. [4.2]
    Wegovy trial shows 10% weight loss maintained after 4 years (CTV News)
    15d
    Source
  15. [5.1]
    Wegovy's long trial shows sustained 10% weight loss, heart protection (CNN)
    15d

  16. [4.6]
    Semaglutide reduces need for diuretics in heart failure patients (Diagnostic and Interventional Cardiology)
    16d
    Source
  17. [3.9]
    Semaglutide improves heart failure symptoms and reduces diuretic dose (News-Medical.Net)
    16d
    Source
  18. [4.5]
    Author suggests India learn from Japan's diet success, caution on weight-loss drugs (BusinessLine)
    16d
    Source
  19. [2.2]
    1 in 8 US adults use GLP-1 drugs like Ozempic (CNN)
    19d
    Source
  20. [3.1]
    Wegovy weight loss drug now available in Canada (CTV News Kitchener)
    21d
    Source